News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
38,064 Results
Type
Article (2429)
Company Profile (39)
Press Release (35596)
Section
Business (14112)
Career Advice (77)
Deals (2076)
Drug Delivery (8)
Drug Development (4098)
Employer Resources (10)
FDA (430)
Job Trends (761)
News (20125)
Policy (1051)
Tag
2024 BioForest Digital (4)
2024 BioMidwest Digital (2)
2024 Biotech Bay Standard (2)
2024 Biotech Beach Digital (1)
2024 Biotech Beach Standard (1)
2024 Lone Star Bio Digital (1)
2024 Pharm Country Digital (1)
2025 Lone Star Bio Digital (1)
Academia (143)
Allergies (4)
Alliances (3467)
ALS (4)
Alzheimer's disease (45)
Antibody-drug conjugate (ADC) (14)
Approvals (432)
Artificial intelligence (9)
Autoimmune disease (2)
Automation (1)
Bankruptcy (11)
Best Places to Work (475)
BIOSECURE Act (2)
Biosimilars (12)
Biotechnology (29)
Bladder cancer (6)
Brain cancer (5)
Breast cancer (17)
Cancer (128)
Cardiovascular disease (4)
Career advice (64)
Career pathing (1)
CAR-T (14)
Cell therapy (41)
Cervical cancer (2)
Clinical research (3169)
Collaboration (88)
Compensation (44)
COVID-19 (180)
CRISPR (7)
C-suite (26)
Cystic fibrosis (2)
Data (102)
Denatured (3)
Depression (3)
Diabetes (9)
Diagnostics (463)
Digital health (1)
Diversity, equity & inclusion (1)
Drug discovery (13)
Drug pricing (7)
Duchenne muscular dystrophy (12)
Earnings (4229)
Editorial (3)
Employer branding (1)
Employer resources (8)
Events (6000)
Executive appointments (87)
FDA (472)
Featured Employer (3)
Funding (74)
Gene editing (14)
Gene therapy (17)
GLP-1 (60)
Government (149)
Healthcare (704)
Huntington's disease (3)
IgA nephropathy (3)
Immunology and inflammation (15)
Indications (2)
Infectious disease (185)
Inflammatory bowel disease (11)
Inflation Reduction Act (6)
Influenza (4)
Intellectual property (10)
Interviews (7)
IPO (986)
IRA (7)
Job creations (290)
Job search strategy (62)
Kidney cancer (4)
Labor market (3)
Layoffs (36)
Leadership (1)
Legal (212)
Liver cancer (5)
Lung cancer (15)
Lymphoma (3)
Management (4)
Manufacturing (18)
MASH (4)
Medical device (306)
Medtech (306)
Mergers & acquisitions (1150)
Metabolic disorders (32)
Multiple sclerosis (6)
Neurodegenerative disease (7)
Neuropsychiatric disorders (3)
Neuroscience (87)
NextGen: Class of 2025 (352)
Non-profit (153)
Northern California (332)
Now hiring (4)
Obesity (15)
Opinion (15)
Ovarian cancer (10)
Pain (8)
Pancreatic cancer (3)
Parkinson's disease (4)
Partnered (1)
Patents (19)
Patient recruitment (2)
Peanut (1)
People (5628)
Pharmaceutical (5)
Phase I (1370)
Phase II (1588)
Phase III (844)
Pipeline (71)
Podcasts (4)
Policy (11)
Postmarket research (30)
Preclinical (588)
Press Release (2)
Prostate cancer (3)
Psychedelics (2)
Radiopharmaceuticals (12)
Rare diseases (21)
Real estate (419)
Recruiting (5)
Regulatory (802)
Reports (6)
Research institute (142)
Resumes & cover letters (9)
Schizophrenia (10)
Series A (24)
Series B (5)
Service/supplier (2)
Sickle cell disease (1)
Southern California (338)
Special edition (1)
Spinal muscular atrophy (2)
Sponsored (1)
Startups (488)
Stomach cancer (1)
Supply chain (4)
The Weekly (1)
United States (1627)
Vaccines (28)
Venture capitalists (7)
Webinars (2)
Weight loss (11)
Women's health (1)
Worklife (1)
Date
Today (23)
Last 7 days (64)
Last 30 days (229)
Last 365 days (2570)
2025 (625)
2024 (2610)
2023 (2858)
2022 (3750)
2021 (4048)
2020 (3471)
2019 (2061)
2018 (1554)
2017 (1795)
2016 (1624)
2015 (1833)
2014 (1369)
2013 (1188)
2012 (1396)
2011 (1332)
2010 (1181)
Location
Africa (43)
Alabama (1)
Arizona (14)
Asia (1860)
Australia (298)
California (773)
Canada (129)
China (38)
Colorado (19)
Connecticut (10)
Delaware (3)
Europe (3804)
Florida (43)
Georgia (5)
Idaho (3)
Illinois (14)
India (1)
Indiana (30)
Japan (7)
Kansas (12)
Maryland (24)
Massachusetts (283)
Michigan (8)
Minnesota (14)
Missouri (3)
Nebraska (1)
Nevada (2)
New Hampshire (2)
New Jersey (66)
New York (45)
North Carolina (88)
Northern California (332)
Ohio (25)
Oklahoma (2)
Oregon (4)
Pennsylvania (45)
Rhode Island (2)
South America (40)
South Carolina (1)
Southern California (338)
Tennessee (2)
Texas (66)
Utah (2)
Virginia (5)
Washington D.C. (1)
Washington State (44)
Wisconsin (6)
38,064 Results for "akston biosciences".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
Dr. Linda Rhodes Joins Akston Biosciences’ Board of Directors
Akston Biosciences Corporation, dedicated to accelerating the biologics revolution in Animal Health, today announced the appointment of Linda Rhodes, VMD, PhD to its Board of Directors.
June 17, 2024
·
3 min read
Genetown
Akston Biosciences’ AKS-452 Vaccine Study Published in Nature, Showcasing Ambifect® Platform’s Versatility
Akston Biosciences, dedicated to accelerating the next revolution in Animal Health, announced the publication in Nature Vaccines of phase II study results for AKS-452, based on Akston’s Ambifect® Fc-fusion protein platform.
February 26, 2024
·
2 min read
Genetown
Akston Biosciences’ AKS-107 Study Published in Frontiers in Immunology, Displaying Ambifect® Platform’s Versatility
Akston Biosciences’ AKS-107 Study Published in Frontiers in Immunology , Displaying Ambifect ® Platform’s Versatility.
March 11, 2024
·
3 min read
Genetown
Akston Biosciences to Focus on Strong Animal Health Pipeline
Akston Biosciences Corporation announced today that it will focus on inventing, developing, and manufacturing breakthrough protein therapeutics for Companion Animal Health, utilizing its versatile Ambifect™ Fc-fusion platform and its Beverly, Massachusetts cGMP biologics manufacturing facility.
August 17, 2023
·
2 min read
Genetown
Akston Biosciences Receives 2023 Most Innovative Award at Animal Health Summit
Akston Biosciences Corporation, which invents, develops and manufactures breakthrough protein therapeutics for Companion Animal Health, received the 2023 Innovation Award at the just-concluded Animal Health Summit in Kansas City, MO.
August 31, 2023
·
2 min read
Genetown
Akston Biosciences CEO to Present at the 2023 Animal Health Summit in Kansas City
Akston Biosciences Corporation, which invents, develops and manufactures breakthrough protein therapeutics for Companion Animal Health, announced that President & CEO Todd Zion, Ph.D., will present at the 2023 Animal Health Summit in Kansas City, MO on August 28, 2023.
August 28, 2023
·
2 min read
Business
Akston Biosciences Strengthens Board with Addition of John T. Preston
Akston Biosciences Corporation, a clinical-stage biotechnology company, today announced that John T. Preston, a founder of TEM Capital, has joined its Board of Directors.
January 23, 2023
·
3 min read
Drug Development
Akston Biosciences Announces Positive Interim Phase II Results from COVID “Universal” Booster Vaccine Trial
Akston Biosciences Corporation, a developer of new classes of biologic therapeutics, today announced top-line clinical results for its Phase II COVID-19 “universal” booster vaccine, AKS-452.
November 1, 2022
·
3 min read
Genetown
Akston Biosciences CEO to Present at the World Vaccine Congress - Apr 12, 2022
Akston Biosciences Corporation, a developer of new classes of biologics, announced that its president and CEO, Todd Zion, Ph.D., has been invited to present at this year’s World Vaccine Congress.
April 12, 2022
·
3 min read
Drug Development
Akston Biosciences Doses First Participants in Phase II Clinical Trial for Shelf-Stable COVID-19 Booster
Akston Biosciences Corporation, a developer of new classes of biologic therapeutics, announced today it dosed the first set of volunteers in an open-label study of AKS-452, its protein subunit COVID-19 vaccine, as a booster.
May 12, 2022
·
5 min read
1 of 3,807
Next
